CN Patent

CN115650965B — 一种瑞卢戈利关键中间体的制备方法

Assigned to Nanjing Weikaier Biomedical Technology Co ltd · Expires 2023-03-31 · 3y expired

What this patent protects

本发明涉及一种瑞卢戈利关键中间体的制备方法，具体涉及(2,6‑二氟苄基)‑[4‑二甲基氨基甲基‑3‑(6‑甲氧基哒嗪‑3‑基氨基甲酰基)‑5‑(4‑硝基苯基)噻吩‑2‑基]氨基甲酸酯（式I）的制备方法，属于有机化学合成领域。本发明提供制备方法具有原材料易于获取、成本低廉、操作简便、环境友好、收率和有关物质稳定的优势，易于工业化生产放大。

USPTO Abstract

本发明涉及一种瑞卢戈利关键中间体的制备方法，具体涉及(2,6‑二氟苄基)‑[4‑二甲基氨基甲基‑3‑(6‑甲氧基哒嗪‑3‑基氨基甲酰基)‑5‑(4‑硝基苯基)噻吩‑2‑基]氨基甲酸酯（式I）的制备方法，属于有机化学合成领域。本发明提供制备方法具有原材料易于获取、成本低廉、操作简便、环境友好、收率和有关物质稳定的优势，易于工业化生产放大。

Drugs covered by this patent

Patent Metadata

Patent number
CN115650965B
Jurisdiction
CN
Classification
—
Expires
2023-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Weikaier Biomedical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.